The identification of mTOR inhibitors as top candidates is expected, considering that the phosphoinositide 3 kinase (PI3K)/ protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway is a key driver of carcinogenesis and progression in BC [27]. This evidence concerns the gene AKT1 and breast cancer.